IOVA vs IMTX vs REPL vs IMCR: The New Battle in Advanced Melanoma

Amtagvi remains the benchmark against which the others are measured

Iovance is the logical starting point because it is the only company in this group built specifically around the industrialization of conventional TIL therapy, and because Amtagvi has already crossed the hardest bridge: turning a highly specialized oncology procedure into a commercially distributable product.

The FDA granted accelerated approval to Amtagvi on February 16, 2024, for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor. The accelerated approval must be confirmed through the Phase 3 TILVANCE-301/IOV-MEL-301 program.

Where Amtagvi is commercialized

Amtagvi is commercially available in the United States and has also received approvals in Canada and Australia. The European path is more complicated: Iovance withdrew its earlier European MAA and said it intends to resubmit with an updated package; a similar dynamic affected the United Kingdom. In other words, despite the scientific first-mover advantage, international expansion remains a major work in progress.

How Amtagvi works

Amtagvi uses T cells already present inside a patient’s tumor. The tumor itself has, over time, selected a population of lymphocytes capable of recognizing multiple tumor antigens. Iovance recovers those cells from tumor tissue, expands them ex vivo to billions of cells, and then reinfuses them into the patient.

Unlike the Immatics TCR-T approach, Amtagvi does not select a single target such as PRAME. This polyclonality is one of the main theoretical advantages of TIL therapy: a heterogeneous tumor may express different antigens across different clones, while a TIL population can potentially recognize multiple neoantigens simultaneously. The price is operational complexity.

The Amtagvi patient journey

1. Tumor procurement

Usable tumor tissue is required. The sample is collected and shipped to the manufacturing facility. That step alone creates a filter: a patient may lack an easily resectable lesion, may be too frail for a procedure, or may have disease progressing too rapidly to wait for manufacturing.

2. Manufacturing

Iovance’s Gen 2 process requires roughly 22 days for cell expansion, followed by testing, release and logistics. Total turnaround therefore exceeds the 22 days of pure cell growth. This remains one of the most attackable points in the Amtagvi workflow.

3. Lymphodepletion

Before infusion, the patient receives a non-myeloablative conditioning regimen with cyclophosphamide and fludarabine. This creates immunologic space for the infused cells, but it also contributes materially to hematologic toxicity and infection risk.

4. TIL infusion

The patient receives the individualized lifileucel dose.

5. High-dose IL-2

After infusion, patients may receive up to six doses of aldesleukin/Proleukin. The cytokine support helps expansion and activity of the T cells but adds substantial clinical burden. Obsidian is trying to eliminate systemic high-dose IL-2 entirely; Immatics uses low-dose IL-2.

Amtagvi efficacy

In the FDA regulatory dataset, the ORR at the recommended dose was approximately 31.5%. Viewed in isolation, that number does not look spectacular. What makes Amtagvi unusual is durability.

The response pattern matters: many patients do not respond, but a subset of responders can derive benefit lasting for years. For a one-time therapy, that characteristic is clinically meaningful and remains central to the value proposition.

Safety: the real price of Amtagvi

Amtagvi carries a Boxed Warning covering treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment. An important share of the toxicity comes from the entire treatment regimen — lymphodepletion, cytopenias, infections, high-dose IL-2 and baseline patient frailty — rather than from the abstract concept of TIL therapy alone.

That is why Amtagvi requires experienced centers and strict patient selection. It is not a product an oncologist simply orders and infuses quickly in a routine outpatient setting.

Manufacturing: moat and risk at the same time

Iovance built the Iovance Cell Therapy Center, or iCTC, and has progressively brought Amtagvi manufacturing in-house. The company has cited potential capacity above 5,000 patients per year. That is a meaningful industrial asset: cGMP facilities, process validation, quality control, cold-chain logistics, chain of identity and know-how with heterogeneous tumor material are not easy to replicate.

But the same infrastructure creates significant fixed costs. The economic value of the moat therefore depends on infusion volume. A high-capacity facility becomes extremely valuable as utilization rises; it becomes burdensome if real-world demand remains below expectations.

Commercialization

In Q1 2026, Iovance generated approximately $60.2 million in Amtagvi revenue and about $11.2 million from Proleukin, for approximately $71.4 million in total product revenue. Amtagvi had grown meaningfully year over year, but the company is not yet economically self-sustaining.

During the quarter, Iovance reported a net loss of roughly $79 million and operating cash use of about $72 million. Cash, cash equivalents, short-term investments and restricted cash were approximately $319 million as of March 31, 2026. The stock is therefore now a commercial-execution story as much as it is a clinical-science story.

Anzu-cel is the most concrete cellular threat over the medium term

Immatics does not yet have an approved product, but among the cellular competitors it has the most advanced path toward possible commercialization in post-PD-1 cutaneous melanoma. Anzu-cel, previously known as IMA203, is an autologous TCR-T cell therapy directed against PRAME.

PRAME is an intracellular cancer antigen. A PRAME-derived peptide is presented on the cell surface through HLA, allowing the engineered TCR to recognize it. The technology is fundamentally different from Iovance’s TIL approach: rather than harvesting a polyclonal population already present inside the tumor, Immatics collects T cells from blood through leukapheresis and engineers them to recognize a defined target.

Development status

Anzu-cel is in Phase 3 SUPRAME, a global, randomized, controlled study in patients with unresectable or metastatic cutaneous melanoma previously treated with a PD-1 inhibitor. The primary endpoint supporting full approval is PFS assessed by blinded independent central review. Secondary endpoints include overall survival, ORR, safety and patient-reported outcomes.

Immatics has targeted a BLA in the first half of 2027 and, subject to approval, a potential U.S. launch in the second half of 2027. The company has also made clear that it may choose not to disclose interim analyses while enrollment continues in order to preserve the statistical integrity of the study.

Anzu-cel efficacy

At ASCO 2026, the RP2D melanoma dataset included 33 treated patients. Among evaluable patients, the overall confirmed ORR was approximately 56%. In cutaneous melanoma, confirmed ORR was approximately 50% (7/14); in uveal melanoma it was approximately 67%.

The signal is strong, but the size of the cutaneous subset is the major caveat. With 14 patients, a single additional or missing responder changes the percentage materially. The real question is whether SUPRAME preserves a clinically meaningful advantage when the program is measured in a large randomized trial.

Anzu-cel’s real advantage is not necessarily ORR

Anzu-cel could be commercially attractive even if final efficacy proves similar to Amtagvi because the patient journey appears simpler.

No tumor surgery

The starting material comes from standard leukapheresis. No tumor resection is required to manufacture the product, no tumor specimen needs to be shipped, and the patient does not have to recover from surgery before conditioning therapy can begin.

Faster manufacturing

Immatics cites approximately 7–8 days of manufacturing plus roughly 7 days for QC release, putting the process around two weeks. In Phase 1, the company reported a manufacturing success rate of approximately 95%. That is a tangible advantage versus the timing of a traditional TIL process.

Low-dose IL-2

After anzu-cel infusion, patients receive low-dose IL-2, with total exposure far below the typical high-dose IL-2 exposure associated with a conventional TIL regimen. Immatics does not eliminate IL-2 completely, as Obsidian is attempting to do, but it sharply reduces the burden.

Safety

In the broader safety population, CRS was predominantly Grade 1–2. A smaller proportion developed Grade 3 CRS, and no Grade 4 CRS was reported in the dataset described. ICANS was observed in a minority of patients. Cytopenias remain common and are largely related to lymphodepletion.

Anzu-cel is therefore not an “easy” therapy. It remains a cellular therapy with conditioning. But the overall burden may prove lower than TIL plus high-dose IL-2.

The major limitation: HLA-A*02:01

Anzu-cel is not universally available. It requires HLA-A*02:01. Immatics has estimated an indicative prevalence of approximately 41% in the United States and roughly 48% in Europe in populations used for commercial planning. That means that even in an excellent Phase 3 scenario, a large proportion of patients would be automatically excluded.

This is one of the most important factors protecting Iovance. Amtagvi does not require HLA selection.

PRAME testing

In the Phase 3 SUPRAME study, Immatics does not require a separate PRAME test for cutaneous melanoma because it considers PRAME prevalence sufficiently high in the HLA-eligible population that HLA testing becomes the main operational filter.

Potential market size

Immatics has estimated roughly 9,000 annually addressable patients across the United States and EU5 when combining second-line cutaneous melanoma and metastatic uveal melanoma in the PRAME+/HLA-A*02:01+ segment. For second-line cutaneous melanoma alone, the company has cited several thousand annual patients in both the U.S. and EU5. These are company estimates and should not be read as implied revenue, but they show that anzu-cel is intended to be a commercially meaningful product rather than a niche therapy.

Manufacturing infrastructure

Immatics has built an approximately 100,000-square-foot GMP facility in Stafford, Texas, with eight manufacturing suites and room for expansion. The site began GMP manufacturing in 2025 and is designed to support both late-stage trials and initial commercial supply.

Financial position

As of March 31, 2026, Immatics reported approximately $521.5 million in cash and financial assets, with runway guided into 2028. For a development-stage biotech simultaneously funding a Phase 3 trial and commercial preparation, that is an important financial position.

As of August 6, the competition is no longer theoretical

TUDRIQEV is the development that immediately changes the competitive map. On August 6, 2026, the FDA approved TUDRIQEV, vusolimogene oderparepvec-wtpg, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who progressed after a PD-1 antibody-based regimen.

It is an accelerated approval, so IGNYTE-3 must verify clinical benefit. Commercially, however, the essential fact is straightforward: a U.S. oncologist now has a second approved option in the same broad post-PD-1 territory.

How TUDRIQEV works

TUDRIQEV is not a cellular therapy. It is a genetically modified HSV-1 oncolytic virus. The virus is designed to replicate preferentially inside tumors, cause cell lysis and release tumor and viral antigens. It includes the fusogenic glycoprotein GALV-GP-R- and GM-CSF, along with additional modifications intended to optimize oncolytic and immunologic behavior.

The concept has two components: local destruction of infected tumor cells and activation of a systemic immune response capable of recognizing lesions that were not directly injected. Demonstrating that systemic effect was one of the central issues in the regulatory debate preceding approval.

Efficacy: two datasets that should not be confused

In the full IGNYTE cohort of 140 patients, Replimune reported approximately 33.6% ORR, median DOR of 24.8 months, median OS of 32.9 months and three-year survival of 47.8%. Those are interesting figures, but they are not the cleanest basis for a regulatory comparison with Amtagvi.

In the efficacy-evaluable population used for approval, comprising 91 patients with at least one non-injected lesion, the reported figures were:

Using the regulatory dataset, Amtagvi currently appears stronger in response depth and, especially, durability. But that does not automatically decide commercial success.

Why TUDRIQEV can take patients from Amtagvi

The operating advantage is obvious. Amtagvi requires tumor procurement, individualized manufacturing, a waiting period, lymphodepletion, infusion and high-dose IL-2. TUDRIQEV instead requires selection of injectable lesions and a course of intratumoral administrations in combination with nivolumab.

There is no personalized cell manufacturing, no multi-week wait to create a patient-specific product, no lymphodepletion and no high-dose IL-2. That can matter greatly for older or frailer patients, patients with comorbidities, or patients whose disease cannot comfortably wait through a lengthy manufacturing cycle.

But it is not “just an injection”

The therapy is intratumoral, so treatable lesions are required. The label allows treatment of superficial, deep and visceral lesions, with image-guided administration when necessary. That broadens the population beyond patients with only easily accessible cutaneous lesions, but it still involves repeated procedures and, in some cases, interventional radiology.

Safety

In the 140-patient cohort, serious adverse reactions were reported in a meaningful proportion of patients. Warnings include accidental exposure, herpetic infection or reactivation, and visceral injury. Most common treatment-related adverse events were low grade.

The operating profile is clearly less intensive than TIL plus lymphodepletion plus high-dose IL-2, but the therapy is neither simple nor risk-free.

Confirmatory trial: IGNYTE-3

IGNYTE-3 is the randomized trial that must confirm clinical benefit. It also matters for the competitive read-through on IOVA: if TUDRIQEV plus nivolumab demonstrates a clear survival benefit versus physician’s choice, the product’s competitive position strengthens substantially. If the benefit is modest, the accelerated approval may prove less disruptive than simple commercial availability initially suggests.

Commercial status

Replimune became a commercial-stage company on August 6, 2026. As of August 7 there is no meaningful series of TUDRIQEV revenues to analyze. The real test starts now: prescribers, reimbursement, center training, administration pathways, coordination with nivolumab and the ability to convert clinical interest into actual use.

Iovance has already accumulated more than two years of commercial learning. Replimune is starting from zero with its first approved product.

Financial position

As of March 31, 2026, Replimune reported approximately $268.9 million in cash, cash equivalents and short-term investments, with runway previously guided into Q1 2027 under the pre-approval operating plan. Approval can improve access to capital and begin to generate revenue, but the launch itself consumes resources.

The most underestimated competitor if you look only at cell therapies

Immunocore does not look much like Iovance from a technology standpoint. That is exactly why it matters. It is not trying to build another TIL product or another autologous cell therapy. Its ImmTAC platform uses soluble bispecific TCR molecules that recognize a tumor peptide presented by HLA and recruit T cells through CD3.

In practical terms, the product is off-the-shelf. That completely removes individualized manufacturing.

KIMMTRAK: proof that the platform works commercially

KIMMTRAK/tebentafusp is approved for HLA-A*02:01-positive unresectable or metastatic uveal melanoma. In Q1 2026, Immunocore reported approximately $106.7 million in net product revenue. The product was approved in dozens of countries and commercialized in more than 30 markets.

IMCR therefore does not need to prove that it can sell an oncology product. It is already doing so.

The clinical result that makes KIMMTRAK important

The pivotal Phase 3 study in uveal melanoma randomized 378 patients. At five years, Immunocore reported:

That is why TEBE-AM deserves close attention. If the cutaneous melanoma program produces a randomized OS advantage, the level of evidence would be extremely difficult to ignore.

KIMMTRAK does not directly compete with Amtagvi in cutaneous melanoma today

Amtagvi is indicated in advanced cutaneous melanoma after PD-1 therapy. KIMMTRAK is currently approved in uveal melanoma. They are not fighting for the same patient today. Immunocore is, however, trying to change exactly that.

TEBE-AM: the catalyst that can change the ranking

TEBE-AM is a registrational Phase 3 study in HLA-A*02:01-positive second-line or later advanced cutaneous melanoma. The study includes three arms: tebentafusp monotherapy, tebentafusp plus pembrolizumab, and investigator’s choice.

The primary endpoint is overall survival. The latest official guidance available points to topline results potentially in the second half of 2026. Among the peers in this report, this trial may represent the biggest potential jump from one competitive category to another.

Why TEBE-AM matters so much for IOVA

If TEBE-AM produced a statistically significant OS advantage with manageable safety, Immunocore would bring randomized Phase 3 evidence, a survival endpoint, off-the-shelf therapy, existing commercial manufacturing, a global commercial organization and an extremely strong financial position.

At that point, the comparison with Amtagvi would no longer be a simple question of “which ORR is higher?” It would become a treatment-sequencing debate built around evidence quality and treatment burden.

The therapeutic burden of tebentafusp

Manufacturing simplicity does not mean absence of burden. KIMMTRAK is administered by weekly intravenous infusion, and the first three infusions require prolonged monitoring because of the risk of cytokine release syndrome. The trade-off versus Amtagvi is therefore very different:

The HLA limitation

Tebentafusp also requires HLA-A*02:01. That restricts the addressable population and continues to provide partial protection for Iovance, which has no such HLA restriction.

Brenetafusp: a second front

Immunocore is not betting everything on tebentafusp. Brenetafusp is a PRAME-targeted ImmTAC. In Phase 1/2 in heavily pretreated melanoma, monotherapy showed a relatively modest ORR of roughly 12%, accompanied by disease-control and survival signals that supported further development.

The program is now in Phase 3 PRISM-MEL-301 in first-line advanced cutaneous melanoma, in combination with nivolumab. The primary endpoint is PFS; secondary endpoints include OS and ORR. This study does not immediately compete with Amtagvi’s current post-PD-1 indication, but it could change the type of patient reaching later lines of therapy.

Financial strength

As of March 31, 2026, Immunocore had approximately $844.9 million in cash, cash equivalents and marketable securities. In Q1 it reported approximately $13 million in net income and more than $100 million in KIMMTRAK product revenue.

Among the four publicly traded peers, IMCR clearly has the strongest financial structure. It can fund global commercialization, TEBE-AM, PRISM-MEL-301 and additional programs simultaneously without depending on an immediate equity financing.

Why Obsidian deserves its own section

Obsidian is the competitor I would watch most closely if the objective is to understand how a TIL could be redesigned to correct Amtagvi’s disadvantages without giving up the biological strengths of TIL therapy.

OBX-115 remains an autologous tumor-infiltrating lymphocyte therapy. It therefore retains tumor-derived T cells and a polyclonal repertoire, but adds engineering.

The technology

OBX-115 expresses membrane-bound IL-15, or mbIL15, which can be pharmacologically regulated through acetazolamide. The objective is to support TIL expansion, activity and persistence without using systemic high-dose IL-2.

If the strategy works as designed, Obsidian will not simply have created “another TIL.” It will have built a TIL with an integrated, controllable cytokine-support system.

Tumor procurement

OBX-115 has been developed to be compatible with a minimally invasive core needle biopsy. That could significantly reduce the need for larger surgical resections, directly attacking another weak point in the Amtagvi pathway.

Lymphodepletion and IL-2

The program uses low-dose lymphodepletion and does not require systemic high-dose IL-2. If that profile holds in larger studies, the number of patients fit enough to receive a TIL therapy could theoretically expand.

Clinical data

In the updated dataset at the recommended Phase 2 dose, with a January 2026 cutoff, Obsidian reported:

Ninety-three percent of patients had received prior immune-checkpoint combinations, and a large proportion had progressed after anti-PD-1 plus anti-CTLA-4 therapy. The signal is therefore interesting even after accounting for the difficulty of the population.

Early safety profile

In the reported data, the small presented dataset showed no dose-limiting toxicities, ICANS, ICU transfers or treatment-related mortality. That is encouraging, but it would be a mistake to extrapolate too far from so few patients.

The maturity problem

Amtagvi’s defense is not its 31% ORR. It is the 36.5-month median DOR. To truly challenge Iovance, OBX-115 must show that a high ORR can be paired with meaningful response durability in a much larger population.

Future development

Obsidian has indicated initiation of the registration-enabling cohort in 2026 and is targeting registration-enabling melanoma data by the end of 2027. The program has received Fast Track and RMAT designations, meaning a structured regulatory dialogue with the FDA is already in place.

Obsidian is moving toward the public market

In 2026, Obsidian and Galera Therapeutics announced a merger agreement accompanied by an approximately $350 million PIPE. The combined company is expected to operate as Obsidian Therapeutics and, once the transaction closes, is expected to trade on Nasdaq under the proposed ticker $OBX.

As of August 7, however, the transaction should not be treated as completed until an official closing is announced. The financing is intended to support the company through multiple readouts into 2028.

Why OBX-115 may be the most interesting technological contender

Obsidian is not trying to replace the TIL concept. It is trying to improve it. If mature data preserve a high ORR and produce durability close to or better than Amtagvi, OBX-115 could become the most problematic competitor for the Iovance franchise. But that “if” remains very large.